GLP-1 Pipeline In November 2023, the FDA approved Zepbound (tirzepatide), a GLP-1 antagonist and GIP dual agonist with superior weight loss efficacy compared to its competitors
Other situations requiring prompt communication with your provider include persistent nausea or vomiting lasting more than 24-48 hours, signs of dehydration (decreased urination, dizziness, dry mouth), visual changes, symptoms of hypoglycemia (shakiness, confusion, rapid heartbeat), or unexplained neck mass or hoarseness
70 A systematic review of 22 studies investigated the effect of intentional weight loss in overweight and obese patients with HF and demonstrated that all forms of weight loss (lifestyle changes, pharmacotherapy or bariatric surgery) are likely to result in significant improvements of symptoms and HRQoL in HF patients
Your clinician selects or combines both based on the depth and type of your pigmentation
Quality You Trust - a trusted name in health and wellness
Reducing hyperpigmentation and the appearance of fine lines, promoting healthy, flawless skin